
Evidence analysis
Human medicines European public assessment report (EPAR): Foundayo, Orforglipron, Status: Opinion
Human Medicines European Public Assessment Report (EPAR): Foundayo (Orforglipron) - Status: Opinion What is Established On 15 October 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Yuviwel, Navepegritide, Status: Opinion
New Medicine Yuviwel for Achondroplasia: An Evidence Dossier What is established Yuviwel is a newly developed medicine containing the active substance navepegritide, a prodrug form of C-type natriuretic peptide (CNP). It is intended for the treatment of achondroplasia…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Iressa, gefitinib, Date of authorisation: 24/06/2009, Revision: 16, Status: Authorised
What is established Iressa is a medicine whose active ingredient is gefitinib, primarily used to treat adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that harbors activating mutations in the epidermal growth factor receptor (EGFR) gene.…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Vizimpro, dacomitinib, Date of authorisation: 02/04/2019, Revision: 4, Status: Authorised
What is established Vizimpro (active substance: dacomitinib) is a medicine approved in the European Union for the treatment of adults with advanced or metastatic non-small cell lung cancer (NSCLC) who have specific mutations in the epidermal growth factor…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Beromun, tasonermin, Date of authorisation: 12/04/1999, Revision: 16, Status: Authorised
What is established Beromun is a medicinal product containing the active substance tasonermin, which is a recombinant form of human tumour necrosis factor alfa-1a (TNFα). The medicine is approved in the European Union for the treatment of soft-tissue…
Read →
Evidence analysis
Five Questions About What’s Behind Nigeria’s Romance Scam Industry
Understanding Nigeria's Romance Scam Industry: Evidence and Analysis This article examines evidence from the Organized Crime and Corruption Reporting Project (OCCRP) about Nigeria’s romance scam industry, based on a 2026 feature exploring the lives and motivations of scammers…
Read →
Evidence analysis
Indonesian Author Faces Blasphemy Probe for Short Stories
Evidence Dossier: Indonesian Author Faces Blasphemy Probe over Short Story Collection What is Established In September 2026, Indonesian police opened an investigation into Feby Indirani, the author of the short story collection Memburu Muhammad (Hunting for Muhammad), on…
Read →
Evidence analysis
Mali: Military Attacks on Civilians, Insurgent Abuses
Human Rights Violations in Mali: Military and Insurgent Abuses Documented This dossier examines recent evidence detailing grave human rights abuses in Mali between July and September 2026. The findings derive primarily from a Human Rights Watch report dated…
Read →
Evidence analysis
EU, Belgium, Denmark: Raise Rights With Vietnam’s Leader
What is established Vietnam’s human rights record has been subject to long-standing international scrutiny. As of October 2026, independent organizations document ongoing repression targeting political activists, rights defenders, journalists, and labor organizers in Vietnam. The government applies restrictive…
Read →
Evidence analysis
Middle East Respiratory Syndrome Coronavirus in Camels, Kazakhstan, 2025
Middle East Respiratory Syndrome Coronavirus in Camels, Kazakhstan, 2025: Evidence Dossier What is established Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a zoonotic betacoronavirus known to circulate primarily among dromedary camels and cause severe respiratory illness in humans.…
Read →